Last reviewed · How we verify
Keverprazan 10 days
Keverprazan is a selective and reversible inhibitor of the sodium-glucose cotransporter 2 (SGLT2).
Keverprazan is a selective and reversible inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Treatment of type 2 diabetes mellitus.
At a glance
| Generic name | Keverprazan 10 days |
|---|---|
| Also known as | Amoxicillin |
| Sponsor | Second Affiliated Hospital, School of Medicine, Zhejiang University |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
By inhibiting SGLT2, keverprazan reduces glucose reabsorption in the kidneys, leading to a decrease in blood glucose levels. This mechanism of action is primarily used to treat type 2 diabetes mellitus.
Approved indications
- Treatment of type 2 diabetes mellitus
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Hypotension
- Increased urination
Key clinical trials
- Optimization of Keverprazan-amoxicillin Dual Therapy for Eradicating Helicobacter Pylori Infection (PHASE3)
- Efficacy and Safety of Keverprazan-amoxicillin Dual Therapy for Helicobacter Pylori First-line Treatment (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: